# OnCo record hr-nmibc (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/hr-nmibc/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "hr-nmibc", "NCT05714202" ;
  schema:name "A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)"@en ;
  schema:alternateName "SunRISe-3"@en ;
  schema:description "A phase 3 trial testing Cetrelimab in bladder & urothelial cancer, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/hr-nmibc/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05714202> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2023-03-23" ;
  onco:cancers <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/non-muscle-invasive-bladder-cancer/> ;
  onco:drugs <https://onco.cc/drugs/cetrelimab/> ;
  onco:companies <https://onco.cc/companies/johnson-johnson/> .